Header

UZH-Logo

Maintenance Infos

Browse by Creators

Navigate back| Up a level
Export as
Number of items: 22.

Berghoff, A S; Kiesel, B; Widhalm, G; Rajky, O; Ricken, G; Wöhrer, A; Dieckmann, K; Filipits, M; Brandstetter, A; Weller, M; Kurscheid, S; Hegi, M E; Zielinski, C C; Marosi, C; Hainfellner, J A; Preusser, M; Wick, W (2015). Programmed death ligand 1 expression and tumor-infiltrating lymphocytes in glioblastoma. Neuro-Oncology, 17(8):1064-1075.

Kurscheid, S; Bady, P; Sciuscio, D; Samarzija, I; Shay, T; Vassallo, I; Criekinge, W V; Daniel, R T; van den Bent, M J; Marosi, C; Weller, M; Mason, W P; Domany, E; Stupp, R; Delorenzi, M; Hegi, M E (2015). Chromosome 7 gain and DNA hypermethylation at the HOXA10 locus are associated with expression of a stem cell related HOX-signature in glioblastoma. Genome Biology, 16(1):16.

Stupp, R; Hegi, M E; Gorlia, T; et al; Kim, C Y; Nabors, L B; Reardon, D A; van den Bent, M J; Hicking, C; Markivskyy, A; Picard, M; Weller, M (2014). Cilengitide combined with standard treatment for patients with newly diagnosed glioblastoma with methylated MGMT promoter (CENTRIC EORTC 26071-22072 study): a multicentre, randomised, open-label, phase 3 trial. Lancet Oncology, 15(10):1100-1108.

Stupp, R; Hottinger, A; Hegi, M E; Weller, M (2013). Diagnostik und Therapie von Gliomen. Swiss Medical Forum, 13(22):421-426.

Bady, P; Sciuscio, D; Diserens, A C; Bloch, J; van den Bent, M J; Marosi, C; Dietrich, P Y; Weller, M; Mariani, L; Heppner, F L; Macdonald, D R; Lacombe, D; Stupp, R; Delorenzi, M; Hegi, M E (2013). Erratum to: MGMT methylation analysis of glioblastoma on the Infinium methylation BeadChip identifies two distinct CpG regions associated with gene silencing and outcome, yielding a prediction model for comparisons across datasets, tumor grades, and CIMP-status. Acta Neuropathologica, 126(1):159.

Weller, M; Pfister, S M; Wick, W; Hegi, M E; Reifenberger, G; Stupp, R (2013). Molecular neuro-oncology in clinical practice: a new horizon. Lancet Oncology, 14(9):e370-e379.

Hegi, M E; Rajakannu, P; Weller, M (2012). Epidermal growth factor receptor: a re-emerging target in glioblastoma. Current Opinion in Neurology, 25(6):774-779.

Bady, P; Sciuscio, D; Diserens, A C; Bloch, J; van den Bent, M J; Marosi, C; Dietrich, P Y; Weller, M; Mariani, L; Heppner, F L; McDonald, D R; Lacombe, D; Stupp, R; Delorenzi, M; Hegi, M E (2012). MGMT methylation analysis of glioblastoma on the Infinium methylation BeadChip identifies two distinct CpG regions associated with gene silencing and outcome, yielding a prediction model for comparisons across datasets, tumor grades, and CIMP-status. Acta Neuropathologica, 124(4):547-560.

Weller, M; Stupp, R; Hegi, M E; van den Bent, M; Tonn, J C; Sanson, M; Wick, W; Reifenberger, G (2012). Personalized care in neuro-oncology coming of age: why we need MGMT and 1p/19q testing for malignant glioma patients in clinical practice. Neuro-Oncology, 14(Suppl. 4):iv100-iv108.

Hegi, M E; Janzer, R C; Lambiv, W L; Gorlia, T; Kouwenhoven, M C M; Hartmann, C; von Deimling, A; Martinet, D; Besuchet Schmutz, N; Diserens, A C; Hamou, M F; Bady, P; Weller, M; van den Bent, M J; Mason, W P; Mirimanoff, R O; Stupp, R; Mokhtari, K; Wesseling, P (2012). Presence of an oligodendroglioma-like component in newly diagnosed glioblastoma identifies a pathogenetically heterogeneous subgroup and lacks prognostic value: central pathology review of the EORTC_26981/NCIC_CE.3 trial. Acta Neuropathologica, 123(6):841-852.

Hegi, M E; Diserens, A C; Bady, P; Kamoshima, Y; Kouwenhoven, M C; Delorenzi, M; Lambiv, W L; Hamou, M F; Matter, M S; Koch, A; Heppner, F L; Yonekawa, Y; Merlo, A; Frei, K; Mariani, L; Hofer, S (2011). Pathway analysis of glioblastoma tissue after preoperative treatment with the EGFR tyrosine kinase inhibitor gefitinib - a phase II trial. Molecular Cancer Therapeutics, 10(6):1102-1112.

Weller, M; Stupp, R; Reifenberger, G; Brandes, A A; van den Bent, M J; Wick, W; Hegi, M E (2010). MGMT promoter methylation in malignant gliomas: ready for personalized medicine? Nature Reviews. Neurology, 6(1):39-51.

Tabatabai, G; Stupp, R; van den Bent, M J; Hegi, M E; Tonn, J C; Wick, W; Weller, M (2010). Molecular diagnostics of gliomas: the clinical perspective. Acta Neuropathologica, 120(5):585-592.

Stupp, R; Hegi, M E; Neyns, B; Goldbrunner, R; Schlegel, U; Clement, P M; Grabenbauer, G G; Ochsenbein, A F; Simon, M; Dietrich, P Y; Pietsch, T; Hicking, C; Tonn, J C; Diserens, A C; Pica, A; Hermisson, M; Krueger, S; Picard, M; Weller, M (2010). Phase I/IIa study of cilengitide and temozolomide with concomitant radiotherapy followed by cilengitide and temozolomide maintenance therapy in patients with newly diagnosed glioblastoma. Journal of Clinical Oncology, 28(16):2712-2718.

Stupp, R; Hegi, M E; Neyns, B; Goldbrunner, R; Schlegel, U; Clement, P M J; Grabenbauer, G G; Ochsenbein, A F; Simon, M; Dietrich, P Y; Pietsch, T; Hicking, C; Tonn, J C; Diserens, A C; Pica, A; Hermisson, M; Krueger, S; Picard, M; Weller, M (2010). Reply to M.C. Chamberlain. Journal of Clinical Oncology, 28(33):e696-e697.

Weller, M; Wick, W; Hegi, M E; Stupp, R; Tabatabai, G (2010). Should biomarkers be used to design personalized medicine for the treatment of glioblastoma? Future Oncology, 6(9):1407-1414.

Stupp, R; Hegi, M E; Mason, W P; van den Bent, M J; Taphoorn, M J B; Janzer, R C; Ludwin, S K; Allgeier, A; Fisher, B; Belanger, K; Hau, P; Brandes, A A; Gijtenbeek, J; Marosi, C; Vecht, C J; Mokhtari, K; Wesseling, P; Villa, S; Eisenhauer, E; Gorlia, T; Weller, M; Lacombe, D; Cairncross, J G; Mirimanoff, R O (2009). Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trial. Lancet Oncology, 10(5):459-466.

Hegi, M E; Liu, L; Herman, J G; Stupp, R; Wick, W; Weller, M; Mehta, M P; Gilbert, M R (2008). Correlation of O6-methylguanine methyltransferase (MGMT) promoter methylation with clinical outcomes in glioblastoma and clinical strategies to modulate MGMT activity. Journal of Clinical Oncology, 26(25):4189-4199.

Gorlia, T; van den Bent, M J; Hegi, M E; Mirimanoff, R O; Weller, M; Cairncross, J G; Eisenhauer, E; Belanger, K; Brandes, A A; Allgeier, A; Lacombe, D; Stupp, R (2008). Nomograms for predicting survival of patients with newly diagnosed glioblastoma: Prognostic factor analysis of EORTC and NCIC trial 26981-22981/CE.3. Lancet Oncology, 9(1):29-38.

Klein, M A; Rüedi, D; Nozaki, M; Dell, E W; Diserens, A C; Seelentag, W; Janzer, R C; Aguzzi, A; Hegi, M E (2000). Reduced latency but no increased brain tumor penetrance in mice with astrocyte specific expression of a human p53 mutant. Oncogene, 19(47):5329-5337.

Hegi, M E; Klein, M A; Rüedi, D; Chène, P; Hamou, M F; Aguzzi, A (2000). p53 transdominance but no gain of function in mouse brain tumor model. Cancer Research, 60(11):3019-3024.

Maddalena, A S; Hainfellner, J A; Hegi, M E; Glatzel, M; Aguzzi, A (1999). No complementation between TP53 or RB-1 and v-src in astrocytomas of GFAP-v-src transgenic mice. Brain Pathology, 9(4):627-637.

This list was generated on Fri Dec 14 03:57:16 2018 CET.